• Long-term culture of neonatal rat SGN with mitotic inhibition by AraC is possible.
Introduction
About 5% of the world's population, over 360 million people, are affected by disabling hearing loss (WHO, 2015) . Most of these patients suffer from sensorineural hearing loss that is characterized by irreversible damage of the sensory epithelium (hair cells) and partial degeneration of the auditory nerve, involving the spiral ganglion neurons (SGN). To date, cochlear implants (CIs) are the sole option for restoring hearing in patients affected by sensorineural hearing loss or deafness. The intracochlear electrode array of the CI enables the electrical stimulation of the SGN. Progressive development of the CI in recent years by means of technical innovations such as novel speech-processing strategies has improved the benefits of these implants for patients. Today, therefore, most implanted patients obtain open speech recognition (Battmer et al., 1999) . However, technical improvements are limited by anatomical conditions in patients, which influence the important nerve-electrode interface. Further improvements to the CI outcome for patients with long-time deafness are, inter alia, affected by retraction of peripheral nerve fibers after hair cell loss and subsequent degeneration of the SGN. This neuronal degeneration occurs much more slowly in humans than in animals (Altschuler et al., 1999; Gillespie and Shepherd 2005; Glueckert et al., 2005; Alam et al., 2007; Liu et al., 2015) . However, the preservation and regeneration of the SGN and their nerve fibers are assumed to be important aspects for further implant improvement.
Previous in vivo studies have detected the potential of simultaneous electrical stimulation and neurotrophic factor (NTF) treatment to increase SGN survival (Lousteau 1987; Hartshorn et al., 1991; Leake et al., 1991 Leake et al., , 1999 Leake et al., , 2011 Mitchell et al., 1997; Shinohara et al., 2002; Yamagata et al., 2004; Roehm and Hansen 2005; Scheper et al., 2009; Shibata et al., 2010) . Additionally, neurite outgrowth of the peripheral spiral ganglion fibers from the modiolus into the scala tympani is reported (Wise et al., 2005 (Wise et al., , 2010 Glueckert et al., 2008; Shibata et al., 2010; Landry et al., 2013) . These in vivo studies are based on cell culture experiments. Explanted primary spiral ganglion cells (SGCs), including the auditory neurons, are a well-established model for exploring their biological response to new therapy strategies for CI improvement. The composition of the cultured cells is influenced by the anatomical conditions of the inner ear. The cell bodies of the bipolar SGN are situated within Rosenthal's canal in the cochlea. Peripheral processes, the dendrites, project from the soma of the SGN through the osseous spiral lamina to the hair cells in the organ of Corti. Together, the central processes -the axons -form the auditory nerve, which terminates in the cochlear nucleus of the brain. Two types of SGN can be distinguished on the basis of factors including their morphology and peripheral target. The large type I SGN project to the inner hair cells -these account for 90-95% of the SGN population -whereas the remaining 5-10% are type II SGN that have a small cell body and connect to the outer hair cells (Spoendlin 1985; Rosbe et al., 1996; Nayagam et al., 2011; Green et al., 2012; Locher et al., 2014) . The perikaryons of the type I and type II SGN are enveloped by satellite glial cells. Myelination of the neuronal cell bodies by this type of glial cell differs between mammalian species. For example, the neuronal somata in the human cochlea are unmyelinated, whereas rat SGN cell bodies are surrounded by thin myelin (Rosenbluth 1962; Romand and Romand 1990; Toesca 1996; Hibino et al., 1999; Liu et al., 2012; Locher et al., 2014) . In contrast to unmyelinated SGN type II nerve fibers, the fibers of type I SGN are sheathed with typical compact myelin, produced by the associated spiral ganglion Schwann cells (SGSCs) (Rosenbluth 1962; Toesca 1996; Wang et al., 2009) , in order to insulate individual ganglion neurons from neighboring neurons and thus prevent electrical interference (Hibino et al., 1999) . SGSCs and satellite glial cells are located in the osseous spiral lamina, Rosenthal's canal and the modiolus (Hurley et al., 2007; Jeon et al., 2011) . Myelination with peripheral myelin synthesized by SGSCs extends from the first node of Ranvier peripherally to the habenula perforata, bordering the organ of Corti, where the dendrites continue unmyelinated. Therefore, the primary cultures derived from cells of Rosenthal's canal contain not only SGNs but also the above-mentioned non-neuronal cells, SGSCs and satellite glial cells (positive for S100 immunolabeling). The ratio of SGSCs and satellite glial cells to SGNs varies widely, between 1:1 (Vieira et al., 2007) , 12:1 (Mattotti et al., 2015) and about 7500:1 (30,000:4) (Hansen et al., 2001) . A small proportion of non-neuronal cells in the SGC culture is accounted for fibroblasts (3%; immunolabeled by vimentin), astrocytes (2%; GFAP-positive) and oligodendrocytes (<0.5%; RIP-positive (Hansen et al., 2001; Furze et al., 2008; Jeon et al., 2011) ).
Glial cells play an important role in neuronal development, survival, regeneration and axonal guidance both in vivo and in vitro. This involves their expressing trophic factors such as brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT3) and ciliary neurotrophic factor (CNTF), and their elaborating extracellular matrix and cell surface proteins for neurite promotion, such as laminin-1, which induces the close association of the neurons and glial cells (Bunge, 1994; Aletsee et al., 2001; Hansen et al., 2001; Boström et al., 2007; Vieira et al., 2007; Whitlon et al., 2009; Clarke et al., 2011; Jeon et al., 2011; Green et al., 2012; He et al., 2014; Sun et al., 2014; Mattotti et al., 2015) .
In dissociated cell culture in vitro, there is a notable increase of the non-neuronal cell number detectable (Hansen et al., 2001; Boström et al., 2007; Whitlon et al., 2009 ), whereas proliferation due to reentry into the cell cycle of glial cells after deafening is considerably limited in vivo (Provenzano et al., 2011) . This proliferation of the non-neuronal cells, especially of neonatal cells, leads to difficulties with long-term cultivation due to overgrowth of the SGN. A more severe problem is that the inevitable presence of other cell types than the SGN introduces an uncontrolled variable in cell culture experiments. Therefore, the effect of treatment strategies -such as surface coatings/structures or exogenous growth factor application on neuronal survival rate or neurite outgrowth and guidance in culture -could be mediated or augmented by the secretion of endogenous factors or molecules from the non-neuronal cells (Staecker et al., 1995; Marzella et al., 1997 Marzella et al., , 1999 Aletsee et al., 2001; Vieira et al., 2007; Whitlon et al., 2009) .
Addition of the mitotic inhibitor cytarabine (AraC), a selective DNA synthesis inhibitor, is an established method of inhibiting fibroblast and glial cell proliferation in neuronal cultures, leading to purification of the Schwann cells and/or neurons (Brockes et al., 1979; Mao and Wang 2001; Negishi et al., 2003; Pettingill et al., 2008; Xiao et al., 2010; Jeon et al., 2011; Provenzano et al., 2011) .
The intention of the present study was to establish a neuronenhanced dissociated SGC culture of neonatal rats cultured for up to seven days, while inhibiting the proliferation of the non-neuronal cells by AraC. Dissociated neonatal SGC-cultures for testing of treatment strategies are commonly performed for two to five days. Therefore the cultured cells were analyzed after four days and the cultivation time of the neonatal cells was prolonged to one week. For a general maintenance of cells, serum (FCS) was added to the culture medium. Compared to that the neurotrophins BDNF and NT3 were chosen as additives for a specific neuronal support and to test these defined and well investigated growth factors in the mitotic inhibited SGC-culture. An additional reason to investigate BDNF and NT3 was that they are produced in vitro by the spiral ganglion Schwann cells. Since the Schwann cells were potentially reduced by mitotic inhibition, we aimed to mimic the production of these NTFs. To estimate the influence of mitotic inhibition, cell composition, neuronal viability and appearance in culture with and without mitotic inhibition were analyzed in order to consider suitability for in vitro testing in auditory research.
Materials and methods

Spiral ganglion cell preparation and dissociation
All experiments were performed in accordance with the German 'Law on Protecting Animals' and with the European Directive 2010/63/EU for protection of animals used for experimental purposes and registered (no. 2013/44) with the local authorities of the Hannover Medical School and reported on a regular basis as demanded by law ( § 4). Early postnatal (P2-4) Sprague Dawley rats of both sexes were dissected for primary cell harvesting for in vitro culture. The detailed preparation procedures have been published previously (Schwieger et al., 2015) . Briefly, the rats were rapidly decapitated, the skull was opened, the brain removed and the temporal bones transferred into a Petri dish (60 × 15 mm; BD Falcon) filled with ice-cold Ca 2+ -/Mg 2+ -free d-phosphate-buffered saline (PBS; Invitrogen). Next, the membranous cochleae were dissected out of the temporal bones, followed by separation of the spiral ganglia and transfer to ice-cold Ca 2+ -/Mg 2+ -free Hank's balanced salt solution (HBSS; Gibco Invitrogen).
Readers are referred to previous descriptions of enzymatical and mechanical dissociation of the SGC (Wefstaedt et al., 2005; Schwieger et al., 2015) . Spiral ganglia were pooled and digested in HBSS containing 0.1% trypsin (Biochrom) and 0.01% DNase I (Roche; 30-40 ganglions/2 ml). After 16 min of incubation at 37 • C, trypsinization was stopped by withdrawal of the supernatant and addition of fetal calf serum (FCS; Invitrogen). FCS, trypsin and DNase were washed out with serum-free culture medium (see below) and the SGC were mechanically dissociated with a 1.000 l pipette tip followed by a 200 l pipette tip (TipOne, StarLab) in 1 ml of the serum-free medium. Trituration was repeated until no cell clusters were visible in the SGC suspension. Afterwards the cell number was counted using the trypan blue (Sigma-Aldrich) exclusion test in a Neubauer chamber (BRAND GmbH). Finally, cells were seeded at a density of 1.4 × 10 4 cells/well in a previously poly-dl-ornithine-(0.1 mg/ml; Sigma-Aldrich)/laminin-(0.01 mg/ml; Naturel Mouse Laminin; Invitrogen) coated 96-multiwell culture plate (Nunc A/S).
Cultivation of spiral ganglion cells
For all performed analyses of neurons and non-neuronal cells under various treatment conditions, cells were cultured in 96-well plates for four and seven days in a medium consisting of Panserin 401 (PAN Biotech) supplemented with 1 M HEPES buffer solution (Invitrogen), PBS, penicillin (30 U/ml; Biochrom), glucose (40%/ml; B. Braun), insulin (4 mg/ml; Biochrom) and N-2 supplement (Invitrogen) in an incubator (CB 150 E3; Binder) at 37 • C, 5% CO 2 and humidity of 95%. Depending on the experimental setup, the serum-free medium was conditioned with 10% FCS or 50 ng/ml BDNF (Invitrogen) with and without 50 ng/ml NT3 (antibodies-online GmbH), and with or without 1.4 g/ml (5 M) AraC (Sigma-Aldrich). Medium was changed every 2-3 days. For cell type-specific staining, SGCs were seeded on poly-dl-ornithineand laminin-coated glass coverslips, and cultured for four and seven days with BDNF and NT3, and with or without AraC. After the appropriate incubation periods, cells were fixed either with a 1:1 acetone (J.T. Baker)/methanol (Roth) solution for neuronal labeling or with a 4% paraformaldehyde (PFA, Merck Millipore) solution for cell type-specific labeling for 10 min at room temperature. Cells were subsequently washed three times using PBS and stored in PBS at 4 • C.
Total cell count
To obtain the total cell number per well, SGC were cultivated in 96-well plates and, for each experimental condition, three independent experiments carried out in triplicate were analyzed. All cells were detached from the well by trypsinization, and the cell number was counted with a Neubauer chamber using the trypan blue exclusion test. Firstly, culture medium was carefully removed and possible residues of medium were washed out using Hank's Salt Solution (Biochrom). Subsequently, 100 l/well of trypsin (0.25%) were added to the cells and incubated for 5 min at 37 • C. After incubation, the detachment of the cells was microscopically monitored and trypsinization stopped by adding 200 l of medium containing 10% FCS. Cells were then resuspended by pipette, and the cell count was performed under inverted light microscope (Olympus CKX 41). If the cells were incompletely resuspended or no cell was counted during the first test, it was repeated and the results were averaged. This method for total cell count was applied to avoid additional washing steps and loss of cells by ICC (see Section 3).
Immunocytochemistry
For analysis of neuronal survival, neurite outgrowth and soma diameter, neurons in culture were labeled specifically for the 200 kD neurofilament. A detailed protocol has been described previously (Wefstaedt et al., 2005) . Briefly summarized, the primary antibody utilized was a monoclonal mouse 200 kD neurofilament (Novocastra) antibody, with subsequent use of the Vectastain ® Elite ® ABC kit (Vector Laboratories) and with a peroxidase substrate kit (DAB; Vector Laboratories) employed for visualization.
As the aim was to investigate the influence of AraC on the cell population in SGC culture, additional immunocytochemical staining for neurons (neurofilament) and non-neuronal cells (S100: glial cells, vimentin: fibroblasts) was carried out (Hibino et al., 1999; Hansen et al., 2001; Hurley et al., 2007; Clarke et al., 2011; Jeon et al., 2011; Anacker et al., 2013) . Cells were permeabilized with PBS containing 0.25% Triton X-100 (Sigma-Aldrich) (PBT) and then blocked using PBS containing 5% FCS and 0.1% Triton X-100. Primary and following secondary antibodies were then added. The neurons were stained against the 200 kD neurofilament, while fibroblasts were labeled with an antibody against vimentin and the glial cells for S100 (Table 1) . Finally ProLong ® Gold antifade reagent with DAPI (Invitrogen) was used for preservation and nucleus labeling. Images were taken with an inverse fluorescence microscope (Olympus BX51, Olympus Life Science) connected to an Olympus XM10 camera (Olympus Life Science), using cellSens software (Olympus Life Science).
Neuron analysis
To evaluate the impact of AraC on neuronal viability, three independent experiments -carried out in triplicate for each conditionwere analyzed for the number of surviving neurons per well, neurite length and soma diameter. In order to determine the effect of the mitotic inhibitor on cell type distribution, the number of neurons as a percentage of the total cell number per well was calculated. Therefore, the total cell number per well, known from the total cell count experiments (Section 2.3), was taken as 100% and the number of counted neurons was set as a percentage of this 100% total cell amount. The number of non-neuronal cells per neuron in the total cell population was calculated, the detected number of surviving neurons per well was then subtracted from the total cell number per well to obtain the proportion of non-neuronal cells, which was finally related to one neuron. Neuron analysis and image taking were conducted using an inverted microscope (Olympus CKX 41) combined with a CCD-camera (Colorview XS, SIS).
Cells labeled positive for neurofilament, having neurites with a length of at least three times that of the soma diameter, were rated as being surviving neurons (Gillespie et al., 2001) and counted for the different experimental conditions and periods of incubation. The neurite length of the SGNs was analyzed based on images taken from at least five fields of view per well (Gillespie et al., 2001) .
Using an image analysis program (CellP, SIS, Olympus), measurements were taken of the neurite outgrowth and soma diameter of 10 randomly selected neurons with the longest clearly traceable neurites per well (two per each field of view) (Gillespie et al., 2001; Berkingali et al., 2008; Kaiser et al., 2013) . Neurons with neurites touching the side of the well or overlapping with other neurites were excluded from the analysis (Vieira et al., 2007) . Measurement was followed by statistical analysis.
Statistical analysis
Data were analyzed as mean ± standard error of the mean (SEM) for statistical significance. The tests applied were the repeatedmeasures one-way analysis of variance (ANOVA) followed by Bonferroni's Multiple Comparison test using GraphPad Prism ® software. Statistical significance was considered at p values less than 0.05.
Results
The results presented focus on the direct comparison of the AraC-treated and AraC-untreated groups, and highlight the most interesting instances of significance in the text. For all such instances found, we refer to the Supplementary material, Tables S1-S5. Furthermore, for clarity's sake, only the relevant means ± SEM are presented in the text. All means ± SEM are summarized in Table 2 .
Total cell count
By counting all surviving cells per well, the effect of mitotic inhibition by AraC on all cells of the SGC culture was detected. In the DAB-stained culture wells, detachment of the overgrowing cell layers ( Fig. 1 ) was noticed in some cases when no AraC was added in the FCS conditions. In the unstained cultures, two wells with FCS-only-treatment showed after change of medium on the fourth day a loss of about 10% of the cell layer. This has led to some cell loss during cultivation, which decreased the number of counted cells and influenced the variability of the results for the uninhibited FCS-culture condition.
The addition of AraC resulted in a reduction of cells in all conditions (FCS, BDNF, BDNF + NT3; four-seven days; Fig. 2 ). After four days of cultivation, a significant reduction of the total cell number was detectable by addition of FCS and AraC compared to FCS without AraC (p < 0.01), but not for the NTF-treated groups. After seven days of incubation, AraC had a highly significant cell-reducing effect in all conditions (FCS: p < 0.001; BDNF: p < 0.01, BDNF + NT3: p < 0.01). While the number of cells increased over time in all conditions without AraC, it decreased with longer incubation with AraC. The highest number of cells for the two analyzed time points was counted, when FCS was added without AraC, after four days (sig- Fig. 1 . Detachment of cells. When SGC were cultivated with 10% FCS and without AraC addition (especially after seven days), the cell layer grew so thick in places that it became locally detached (→) from the plate. No detachment of cells was observed in the NTF-treated or AraCtreated conditions. SGC underwent neuron-specific staining for neurofilament with DAB. Magnification: 40×. Effect of AraC (1.4 g/ml) and different factors (10% FCS, 50 ng/ml BDNF and 50 ng/ml BDNF + 50 ng/ml NT3) on the total cell number per well after four and seven days in vitro. Each condition with AraC is plotted and compared against the same condition without the inhibitor. The statistically significant differences are plotted above the relevant AraC bar (i.e., the dotted bars). After four days of culture, the highest cell population was measured in FCS-conditioned SGC culture. The detected significances for the 4d FCS-treatment are marked on the lower line referring to the FCS 4d bar. With AraC, the cell number decreased significantly (FCS + AraC 4d; p < 0.01). After seven days, all treatment groups with AraC had significantly lower cell counts than without AraC. At this time point and with the addition of FCS, the number of cells was higher -and significantly so -than all other conditions. These significances are plotted on the upper line referring to the FCS 7d bar (mean ± SEM; **p < 0.01; ***p < 0.001; ns = not significant; independent experiments = 3, wells = 3) nificant difference compared to all AraC-treated groups; p < 0.01) and after seven days (significant difference compared with all other groups; p < 0.01 and p < 0.001; Fig. 2 ).
Neuronal survival
The number of surviving neurons per well was counted for each condition. In the FCS-treated, AraC-untreated wells, local detachment of the first cell layer (Fig. 1) in the four day cultures was observed. Except for one well with about 30% of detachment, the area of detachment was approximately under 5%. The detachment was mainly limited to the non-neuronal cells, except after seven days of cultivation. Here the overgrowing non-neuronal cell layers were extensively washed away. In three wells 10-30% and in two wells 2-5% of the SGN-containing undermost layer was detached. This may have resulted in local loss of single neurons for the serum containing, AraC-untreated conditions, and these detached areas were excluded from analysis.
AraC did not reduce the number of neurons when compared with the relevant AraC-untreated controls. Overall, this number tended to decrease over time. The quantity of neurons was increased by treatment with BDNF and NT3 after four and seven days of cultivation, with the best neuronal survival rates observed after four days of incubation with BDNF and NT3 supplemented with AraC. This number of neurons was significantly higher than when using FCS with AraC after four days (p < 0.01), and FCS and BDNF with and without AraC after seven days of cultivation (p < 0.05 and p < 0.01) (Fig. 3) .
Percentage of neurons
The total cell number per well was taken as 100%, and the number of neurons in each case is given as a percentage of this total. Adding the mitotic inhibitor AraC resulted in an increased ratio of neurons to non-neuronal cells. This increase was significant for all conditions analyzed after seven days in culture with AraC. Treat- Fig. 3 . Neuronal survival. Different conditions (10% FCS, 50 ng/ml BDNF and 50 ng/ml BDNF + 50 ng/ml NT3) of SGC culture were analyzed for the number of surviving neurons per well (with addition and withdrawal of the mitotic inhibitor AraC (1.4 g/ml) after four and seven days of in vitro cultivation). There was no significant (ns) negative effect of AraC on the number of neurons detectable for the various conditions compared, as indicated above the relevant AraC treatment bars. The highest number of neurons was counted after four days of cultivation with BDNF, NT3 and AraC, with significant differences compared to both FCS conditions (with and without AraC) after four and seven days, and differences to the BDNF with and without AraC-treated cells after seven days (significances plotted on the line, referring to the BDNF + NT3 + AraC 4d bar). One general observation was the tendency for neuron number to decrease over time. Differences for the conditions with and without mitotic inhibitor addition are marked above the AraC error bars (mean ± SEM; *p < 0.05; **p < 0.01; ns = not significant; independent experiments = 3, wells = 3).
Fig. 4. Percentage of neurons in culture.
The bar chart plots the effect on the percentage of SGN in the SGC culture of different factors (10% FCS, 50 ng/ml BDNF and 50 ng/ml BDNF + 50 ng/ml NT3), each combined with 1.4 g/ml AraC for four and seven days in vitro. The proportion of SGN was significantly increased by the addition of AraC for all conditions after seven days. Asterisks and 'ns' above the AraC error bars show the significance of the AraC conditions compared to the relevant negative control without AraC. The combination of BDNF and NT3 with AraC on cultured cells for seven days resulted in the highest percentage of neurons per well -and by a significant margin -compared to most of the other conditions (see line with asterisks corresponding to the BDNF + NT3 + AraC 7d bar) (mean ± SEM; *p < 0.05; ***p < 0.001; ns = not significant; independent experiments = 3, wells = 3) ment with BDNF, NT3 and AraC for seven days resulted in the highest neuronal fraction, with a significant margin for all AraCuntreated conditions (p < 0.001). Additionally, 7 day treatment with BDNF, NT3 and AraC significantly increased the percentage of neurons compared to four days cultivation of serum + AraC and BDNF + AraC. With this treatment, the proportion of SGNs achieved was about 16% (16.31 ± 1.76%; Fig. 4) .
Number of non-neuronal cells per neuron
The number of non-neuronal cells per neuron was calculated by deducting the detected number of surviving neurons per well from the total cell number per well, which was then related to one neuron. This number increased over time when mitosis was not inhibited. When FCS without AraC was added to the cells for four days, the quantity of non-neuronal cells per neuron was 123.6 ± 10.27. One week of cultivation with FCS and without AraC resulted in an almost 10-fold higher cell-neuron ratio with 1173 ± 738.8 cells per neuron. With NTF treatment, the number of non-neuronal cells after seven days (114.1 ± 11.81) only approximately doubled compared to the cell number after four days (49.99 ± 8.52) of incubation. AraC treatment resulted after seven days in about half of the number of non-neuronal cells compared with four-day culture (Table 2) . No statistical differences were detected between groups (Fig. 5) . The bar chat plots the number of non-neuronal cells per SGN in the SGC culture under different culture conditions (10% FCS, 50 ng/ml BDNF and 50 ng/ml BDNF + 50 ng/ml NT3, each with and without 1.4 g/ml AraC) after four and seven days of cultivation. There is a noticeable tendency for the number of non-neuronal cells per neuron to decrease where AraC is added, and for this number to increase over time without mitotic inhibition. Data are presented as mean ± SEM.
Different cell types
Using immunocytochemistry for 200 kD neurofilament (NF), vimentin and S100, three different cell types were detected in the SGC culture after seven days of incubation (Fig. 6) . Next to the NF-positive SGN population there was the population of nonneuronal cells, in the main vimentin-positive and S100-positive, with bipolar morphology, being spindle-shaped, and hence glial cells. A smaller proportion of the non-neuronal cells was labeled positive for vimentin but negative for S100, and exhibited a broad-based stellate morphology typical of fibroblasts. Very few cells were labeled for DAPI and none of the cell type-specific antibodies. Without addition of the mitotic inhibitor AraC, the nonneuronal cells formed a monolayer, with the neurons integrated (Fig. 6A) . When the ratio of non-neuronal cells was decreased by AraC-mediated inhibition of cell division, nearly all fibroblasts and a large proportion of the glial cells were eliminated (Fig. 6B) . As indicated in Fig. 6B , glial cells chiefly remain neuron-/neuriteassociated in the culture after AraC treatment.
Neurite outgrowth and soma diameter
Neurite outgrowth in terms of neurite length and soma diameter was measured as an indicator of neuronal health after AraC substitution. No negative effects of AraC on neurite outgrowth (Fig. 7A ) and soma diameter (Fig. 7B) were detected when compared with the AraC-free controls. The shortest neurites were measured after treatment of the SGC with FCS and AraC for four days (513.3 ± 22.02 m), with significant differences compared to all other conditions (p < 0.05-p < 0.001), except for four days' treatment with FCS only or BDNF with AraC. Where cells After seven days of cultivation with normal cell division, most non-neuronal cells were labeled positive for S100 (glial cells, yellow; A). A marked reduction of vimentin-positive cells (fibroblasts, red) and, in particular, S100-labeled cells, is observable where mitosis is inhibited for seven days (B). The remaining nonneuronal cells were mainly located close to the SGN (neurofilament-positive, green). Cell nuclei and cell debris were labeled by DAPI (blue). SGN somata are marked by asterisk, small arrows point on single fibroblasts and thick arrows indicate fibroblast clusters. Magnification 100×.
were treated with only BDNF for seven days, the longest neurites were regenerated (1260 ± 35.09 m) significantly compared to all four-day conditions and FCS with AraC for seven days (p < 0.05-p < 0.001). Comparing the various treatment groups at both four and seven days, a significant increase in neurite length over time was detected for FCS with AraC, BDNF with and without AraC, and BDNF + NT3 without AraC addition (Supplementary material) (p < 0.05-p < 0.001).
The soma diameter of four-day-cultivated SGN did not differ between treatment conditions. Compared with cells cultivated for seven days, those treated with FCS + AraC for four days were significantly reduced compared to neurons treated with FCS + AraC, BDNF, BDNF + NT3 and BDNF + NT3 + AraC ( Fig. 7B ; p < 0.05-p < 0.001). The largest soma diameter was measured after treatment with BDNF + NT3 for seven days (18.61 ± 0.34 m), i.e., a significant increase compared to BDNF + AraC, BDNF and BDNF + NT3 after four days of treatment (p < 0.05-p < 0.01). A significant increase in soma diameter over time (four to seven days) was detected for FCS with AraC and BDNF without AraC (Supplementary material) (p < 0.05) (Fig. 7B) .
With AraC-addition, the neurites remain partly free of surrounding non-neuronal cells with a direct contact to the surface of the culture plate. And there was one additional finding that was both interesting and unexpected. During measurement of neurite length, phenomena were observed that had not been seen before under standard culture conditions: namely, morphological changes with increased branching and a tendency among the neurites of the SGN (Fig. 8 ) towards fasciculation and connection following a strong reduction in the amount of non-neuronal cells. This effect was most conspicuous after seven days of incubation with BDNF + NT3 and cell growth inhibition, which also correlated to the highest neuron density of all conditions (see above).
Discussion
SGC culture is a widely used method in basic auditory research. This culture contains neurons, fibroblasts and glial cells. Due to cell division of the non-neuronal cells, especially of neonatal SGC, and known apoptosis of neurons over time of cultivation, the balance between neuronal and non-neuronal cells is impaired and Fig. 7 . Neurite outgrowth and soma diameter. Neurite length (A) and soma diameter (B), measured in m, were analyzed for the influence of 1.4 g/ml mitotic inhibitor AraC with different factors added (10% FCS, 50 ng/ml BDNF and 50 ng/ml BDNF + 50 ng/ml NT3) for four and seven day SGC culture. Neither neurite outgrowth nor soma diameter differed significantly in each condition when AraC was added. The shortest neurites were measured after four days of incubation with FCS and AraC (in some cases significantly, plotted on the lower line referring to the FCS + AraC 4d bar in A). And the longest neurites were measured after seven days of incubation with BDNF and without AraC. Significances compared to BDNF 7d-treatment are plotted on the upper line (A). The smallest soma diameters were observed after treatment with FCS and AraC for four days, which were significantly smaller compared to some seven day treatment groups (plotted on the lower line in B). After seven days of cultivation with BDNF + NT3 but without AraC, the (in some cases significantly, see asterisk on the upper line in B) largest soma were observed. The absence of significant differences between the conditions in respect of mitotic inhibitor (AraC) addition or withdrawal is indicated above the AraC error bars (mean ± SEM; *p < 0.05; **p < 0.01; ***p < 0.001; ns = not significant; independent experiments = 3, wells = 3). long-term in vitro studies being performed on these neurons are hindered. Reducing the seeding density to avoid overgrowth and detachment is not an option, as this would also reduce the number of neurons available for examination such that no differences between treatment and control would be detectable anymore. Furthermore, proliferating non-neuronal cells may influence the evaluation of strategies to treat SGN.
This study is the first to report a protocol for long-term cultivation of neonatal primary auditory neurons with a reduced glial proportion by using the mitotic inhibitor AraC. The addition of AraC reduces the proliferation of non-neuronal cells without affecting the viability of the SGN. Although a neurotoxic effect of AraC in vitro is reported (Wallace and Johnson, 1989; Courtney and Coffey, 1999; Leeds et al., 2005; Delivopoulos and Murray 2011) AraC did not lead to a decrease in neuronal survival rate, neurite length or soma diameter compared to AraC-untreated neurons in the here presented study. The hypothetical negative effect of AraC on SGN was also possibly avoided by the used low dose of 1.4 g/ml (5 M) of AraC. For example a concentration of 10 M AraC in vitro is indicated as a non-toxic dose for cerebellar granule neurons (Courtney and Coffey, 1999; Leeds et al., 2005) . The reduced trophic support due to lower numbers of non-neuronal cells had no effect on the SGN in this study. The known survival rate-enhancing and neurite length-enhancing effects of BDNF and NT3 application (Lefebvre et al., 1994; Hegarty et al., 1997; Mou et al., 1997; Malgrange et al., 1998; Warnecke et al., 2007; Green et al., 2012; Xie et al., 2013) were not decreased by the reduced number of non-neuronal cells resulting from AraC treatment. This justifies the assumption that the beneficial influence of BDNF and NT3 is a direct effect on the neurons and not mediated by the proliferating nonneuronal cells. Adding growth factors in addition to AraC treatment greatly increased the proportion of neurons in the primary SGC culture from below 1% after four days' cultivation with only serum to over 16% after one week with the NTFs. Moreover, the number of non-neuronal cells per neuron was massively decreased after seven days from, for example, 1173:1 with FCS addition and without AraC, to 5:1 with BDNF + NT3 + AraC.
Under the experimental conditions of this study without mitotic inhibition, the total number of cells rose over time. The slightly reduced number of SGN indicates that the increase in total number of cells was due to proliferation of non-neuronal cells. This is consistent with previous studies in which fibroblasts and glial cells proliferate in peripheral nerve culture but neurons do not (Brockes et al., 1979; Hansen et al., 2001; Boström et al., 2007; Whitlon et al., 2009) . The most abundant non-neuronal cells detected in the culture used in the present study were cells that were S100-positive and spindle-shaped and hence glial cells (SGSCs and satellite cells). This is consistent with the findings of Hansen et al. (2001) , namely with >95% of the non-neuronal cells determined as S100-positive SGSCs, and those of Mattotti et al. (2015) , with S100-positive cells accounting for about 60%. Without AraC, the distribution of nonneuronal cells in the well was diffuse (Figs. 6 A and 8 A and C). After AraC treatment, the glial cells were mainly neuron-associated, and vimentin-positive cells with fibroblastic morphology were very rare (Figs. 6 B and 8 B and D) . This might indicate that neuron-associated glial cells proliferate more slowly and therefore survive mitotic inhibition. Hansen et al. (2001) described FCS as being a Schwann cell mitogen. This is confirmed by the markedly increased number of non-neuronal cells after incubation with FCS in the experiments described here. Another possible explanation for the glial-neuron association would be that the remaining SGSCs migrate to the neurons to interact with them (Boström et al., 2007) . Very few cells in the analyzed culture were not labeled by the cell type-specific antibodies (approximately 2%), which is in accordance with previous findings (Hansen et al., 2001; Jeon et al., 2011) .
It is discussed in the literature that the results of experiments investigating the effects of growth factors on, for instance, SGN survival rate and neurite outgrowth or guidance tested in vitro, are influenced by uncontrolled proliferation of SGSCs (Staecker et al., 1995; Marzella et al., 1997 Marzella et al., , 1999 Aletsee et al., 2001; Vieira et al., 2007) . For example, Hansen et al. (2001) demonstrated that BDNF and NT3 are expressed in dissociated cultured SGSCs. It is also demonstrated that, in vivo, the proliferation of SGSCs is limited after reentry into the cell cycle following deafening (Provenzano et al., 2011) . Deafened animals exhibited significantly higher levels of SGSC proliferation, as proven by BrdU uptake, than in normal-hearing animals, whereas the total number of SCs remained stable. In the present study, the proliferation of nonneuronal cells was slower under NTF treatment (i.e., rapid with FCS), while the number of surviving neurons -and therefore the neuronal proportion -was increased. Thus, under mitotic inhibition using AraC, the ratio of neurons to non-neuronal cells increased over time, whereas the number of neurons in relation to that of non-neuronal cells decreased over time without AraC. In the present study, the ratio of non-neuronal cells (mainly S100-positive SGSC and satellite cells) to neurons shows an extremely wide range from 5:1 (BDNF + NT3 + AraC after 7d) to 1173:1 (FCS after 7d). Ratios described in the literature also vary, from 1:1 (Vieira et al., 2007) and 12:1 (Mattotti et al., 2015) to 7500:1 (30,000:4) (Hansen et al., 2001 ). This might be related to the animals themselves (neonatal, adult, species), the cultivation time or the medium used, as well as to addition or withdrawal of NTFs and/or serum. Vieira et al. (2007) cultivated adult mouse SGC in neurobasal medium (+B-27 supplement) enriched with BDNF, leukemia inhibitory factor (LIF) and NT3 for four days. Mattotti et al. (2015) investigated dissociated P5 rat SGCs for one to seven days in the same medium, but with the addition of glial cell line-derived neurotrophic factor (GDNF). Hansen et al. (2001) examined P5 rat SGC for four days (in the absence of NTFs) in DMEM to which N-2 supplement was added. Our finding most comparable to that of these experimental setups is the result for the cell-neuron ratio after four days with BDNF and NT3 with 50:1 non-neuronal cells per neuron. In contrast to these other setups, in the present study complemented panserin was used as the basal medium (a standard medium for NTF-treatment testing on SGC), NTF/serum was added and the SGCs were derived from P2-4 rats. These differences may account for the reduced viability of SGN (Warnecke et al., 2007; Kaiser et al., 2013) . Jin et al. (2013) observed that the density of nonneuronal cells decreased with increasing age (P0-P20) of the donor animal. This might explain why dissociated SGC of mature animals could be maintained for several weeks Boström et al., 2007; Wei et al., 2007) , whereas we observed detachment of cells after only one week as a function of additive use. With a combined AraC-and NTF-treatment the ratio of non-neuronal cells to neurons for our neonatal SGC-culture (5:1 after 7d) is more similar to the documented ratio of 1:1 (Vieira et al., 2007) for adult SGC-culture. In the recent study with AraC addition, neurites partly free of surrounding non-neuronal cells were observed. Additionally we noticed changes in the neurite outgrowth with a tendency among the neurites regenerated from the SGNs towards fasciculation and connection.
This was most prominent after seven days in culture under treatment with both NTFs and the mitotic inhibitor. This effect was not, however, observed where glial proliferation was unaffected. The reduced number of SGSCs in AraC-treated conditions may have led to the changes in the branching and course of the neurites. Physiologically, Schwann cells are associated with the neurites of the SGN. In situ, the neurites are unmyelinated peripherally to the habenula perforata (Hurley et al., 2007; Locher et al., 2014) due to absence of SGSCs behind this anatomical barrier to the organ of Corti, where they connect to the hair cells. Furthermore, regenerated nerve fibers in the scala tympani (Roehm and Hansen 2005; Wise et al., 2005 Wise et al., , 2010 Shibata et al., 2010; Landry et al., 2013) , where the cochlear implant electrode array is situated, are not surrounded by SGSCs, this being due to a lack of glial cells beyond the osseous spiral lamina. In vitro, the associated SGSCs align the SGNs and also guide the regenerated neurites (Boström et al., 2007 (Boström et al., , 2010 Clarke et al., 2011; Khalifa et al., 2013) . Other studies have demonstrated that the non-neuronal cells form a monolayer in culture that the SGN neurites use as a matrix to grow on, and on which they avoid touching each other (Aletsee et al., 2001; Brors et al., 2002; Boström et al., 2007; Furze et al., 2008) . In vitro, there is no barrier such as the habenula perforata to isolate the peripheral ending of the dendrites from glial cells. In view of this, we hypothesize that the observed formation of connected neurites might be caused by the reduced number of glial cells and therefore a lack of guidance and isolation.
Previous in vitro studies showing connection or network formation and synapse-like contacts between SGN were carried out on adult cultured dissected inner ear neurons (Boström et al., 2007) , adult mouse SGN (Wei et al., 2007) or adult human and guinea pig neurosphere-derived SGN (Rask-Andersen et al., 2005) after longterm cultivation. The morphological findings of these studies are similar to the findings presented here. This may indicate that the long-term cultivation of neonatal SGN with reduced proliferation of glial cells by mitotic inhibition, and treatment of the neurons with NTFs (such as BDNF and NT3), may induce the formation of neuronal connections similar to those of cultured adult SGN with slowly proliferating glial cells. It is possible, that guidance of the neurites by the SGSCs in AraC-untreated culture inhibits the connections between neurons. The use of BDNF and NT3 might play an important role in any connections, since both factors are known to promote, inter alia, neuronal survival and neurite outgrowth, as well as synaptogenesis and synaptic strength as reviewed by Green et al. (2012) .
With the technique presented in this study, the neurons can still associate with SGSCs and satellite cells but uncontrolled proliferation of the glial cells is prevented. Furthermore, the neurites are in some cases not surrounded by glial cells, which might enable them to form connections. The AraC-inhibited glial cell proliferation and the (in part) SGSC-free SGN neurites could reflect a more physiological organization of the SGC in vitro and therefore allow new experimental setups for analysis (of connection) of regenerated neurites to target cells or an implant. This is particularly interesting for tests of the interaction of neurites with surfaces. For auditory research on regeneration and guidance of neurites from auditory neurons to improve the CIs, this may represent a considerable benefit. Longer-term observation of neonatal SGC in culture is also possible, as is the detection of a more direct impact of treatments on the neurons in vitro. It is also possible that the cultivation procedure described could be used in more in-depth investigation (and therefore more detailed understanding) of SGN-glial cell interaction.
